288 related articles for article (PubMed ID: 30713313)
1. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy.
Onda A; Miyagawa S; Takahashi N; Gochi M; Takagi M; Nishino I; Suzuki S; Oishi C; Yaguchi H
Intern Med; 2019 Jun; 58(11):1635-1638. PubMed ID: 30713313
[TBL] [Abstract][Full Text] [Related]
2. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
3. [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis].
Isami A; Uchiyama A; Shimaoka Y; Suzuki S; Kawachi I; Fujita N
Rinsho Shinkeigaku; 2019 Jul; 59(7):431-435. PubMed ID: 31243249
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
5. [A case of sporadic late-onset nemaline myopathy associated with myasthenia gravis positive for anti-titin antibody and anti-Kv1.4 antibody].
Kanatani M; Adachi T; Sakata R; Watanabe Y; Hanajima R
Rinsho Shinkeigaku; 2020 Jul; 60(7):489-494. PubMed ID: 32536668
[TBL] [Abstract][Full Text] [Related]
6. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-induced myasthenia gravis: A fatal case report.
March KL; Samarin MJ; Sodhi A; Owens RE
J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
[TBL] [Abstract][Full Text] [Related]
8. [A case of myasthenia gravis developed during pembrolizumab administration, suggesting an excitation-contraction connection disorder].
Fukazawa R; Takezawa H; Tsuji Y; Noto Y; Banba M; Fujii A
Rinsho Shinkeigaku; 2020 Jan; 60(1):37-40. PubMed ID: 31852868
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
10. Pembrolizumab-induced Myopathy with Anti-striated Muscle Antibodies Successfully Treated by Plasma Exchange.
Takahashi S; Okabayashi K; Soejima I; Oniki A; Ishihara S; Tomimitsu H
Intern Med; 2023; 62(23):3525-3530. PubMed ID: 38044116
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab-associated ocular myasthenia gravis.
Liu Q; Ayyappan S; Broad A; Narita A
Clin Exp Ophthalmol; 2019 Aug; 47(6):796-798. PubMed ID: 30859689
[No Abstract] [Full Text] [Related]
12. A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis.
Stefanou MI; Komorowski L; Kade S; Bornemann A; Ziemann U; Synofzik M
BMC Neurol; 2016 Sep; 16(1):172. PubMed ID: 27623618
[TBL] [Abstract][Full Text] [Related]
13. Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen.
Stergiou C; Lazaridis K; Zouvelou V; Tzartos J; Mantegazza R; Antozzi C; Andreetta F; Evoli A; Deymeer F; Saruhan-Direskeneli G; Durmus H; Brenner T; Vaknin A; Berrih-Aknin S; Behin A; Sharshar T; De Baets M; Losen M; Martinez-Martinez P; Kleopa KA; Zamba-Papanicolaou E; Kyriakides T; Kostera-Pruszczyk A; Szczudlik P; Szyluk B; Lavrnic D; Basta I; Peric S; Tallaksen C; Maniaol A; Gilhus NE; Casasnovas Pons C; Pitha J; Jakubíkova M; Hanisch F; Bogomolovas J; Labeit D; Labeit S; Tzartos SJ
J Neuroimmunol; 2016 Mar; 292():108-15. PubMed ID: 26943968
[TBL] [Abstract][Full Text] [Related]
14. [A case of anti-acetylcholine receptor antibody-positive ocular myasthenia gravis with anti-titin antibody and anti-Kv1.4 antibody positive inflammatory myopathy].
Fuse K; Araki A; Morozumi S; Yasui K; Kazuta T; Noda S; Katsuno M
Rinsho Shinkeigaku; 2023 Dec; 63(12):830-835. PubMed ID: 37989286
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
[TBL] [Abstract][Full Text] [Related]
16. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
[No Abstract] [Full Text] [Related]
17. Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report.
Kim JS; Nam TS; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2019 Oct; 10(10):2045-2049. PubMed ID: 31436031
[TBL] [Abstract][Full Text] [Related]
18. Ocular myasthenia and nitrofurantoin.
Wasserman BN; Chronister TE; Stark BI; Saran BR
Am J Ophthalmol; 2000 Oct; 130(4):531-3. PubMed ID: 11024434
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of signs in ocular myasthenia gravis and correlation with acetylcholine receptor antibodies.
Francis IC; Nicholson GA; Kappagoda MB
Aust N Z J Ophthalmol; 1985 Nov; 13(4):395-9. PubMed ID: 3833299
[TBL] [Abstract][Full Text] [Related]
20. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
[Next] [New Search]
